Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy
Bryan J Donald,1,2 Salim Surani,3–5 Harmeet S Deol,1,6 Uche J Mbadugha,1 George Udeani1,7 1Department of Pharmacy, Corpus Christi Medical Center, Corpus Christi, TX, 2Department of Clinical Sciences, School of Pharmacy, University of Louisiana at Monroe, Monroe, LA, 3Department of Pulmono...
Main Authors: | Donald BJ, Surani S, Deol HS, Mbadugha UJ, Udeani G |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-12-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/spotlight-on-solithromycin-in-the-treatment-of-community-acquired-bact-peer-reviewed-article-DDDT |
Similar Items
-
Staphylococcus aureus with an erm-mediated constitutive macrolide-lincosamide-streptogramin B resistance phenotype has reduced susceptibility to the new ketolide, solithromycin
by: Weiming Yao, et al.
Published: (2019-02-01) -
Community-acquired bacterial pneumonia in adults: An update
by: Vandana Kalwaje Eshwara, et al.
Published: (2020-01-01) -
Mycoplasma pneumoniae: Atypical Pathogen in Community Acquired Pneumonia
by: Abdul-Rahman Mamdouh Mohammad, et al.
Published: (2020-12-01) -
Macrolides in the modern therapy of community-acquired pneumonia in children
by: Yu. L. Mizernitskiy
Published: (2020-11-01) -
Macrolide-resistant <it>Mycoplasma pneumoniae</it> in adolescents with community-acquired pneumonia
by: Miyashita Naoyuki, et al.
Published: (2012-05-01)